A O
clinical B-STYPE
study E-STYPE
of O
traditional O
Chinese O
medicine O
prolonging O
the O
survival O
of O
advanced O
gastric O
cancer O
patients O
by O
regulating O
the O
immunosuppressive O
cell O
population O
A O
study B-STYPE
protocol E-STYPE
for O
a O
multicenter B-STYPE
, I-STYPE
randomized I-STYPE
controlled I-STYPE
trail E-STYPE
A O
clinical B-STYPE
study E-STYPE
of O
traditional O
Chinese O
medicine O
prolonging O
the O
survival O
of O
advanced O
gastric O
cancer O
patients O
by O
regulating O
the O
immunosuppressive O
cell O
population O
A O
study B-STYPE
protocol E-STYPE
for O
a O
multicenter B-STYPE
, I-STYPE
randomized I-STYPE
controlled I-STYPE
trail E-STYPE
BSXiaotingPan S-AUTH
 
Traditional O
Chinese O
Medicine O
Hospital O
of O
Zhangjiagang O
, O
d O
Changzhou O
TCM O
Hospital O
, O
e O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Kunshan O
, O
f O
Jiangsu O
Cancer O
Hospital O
, O
g O
Nanjing O
Drum O
Tower O
Hospital O
China O
MSShenlinLiu S-AUTH
 
A O
clinical B-STYPE
study E-STYPE
of O
traditional O
Chinese O
medicine O
prolonging O
the O
survival O
of O
advanced O
gastric O
cancer O
patients O
by O
regulating O
the O
immunosuppressive O
cell O
population O
A O
study B-STYPE
protocol E-STYPE
for O
a O
multicenter B-STYPE
, I-STYPE
randomized I-STYPE
controlled I-STYPE
trail E-STYPE
10.1097 O
/ O
MD.0000000000019757 O
 
A O
clinical B-STYPE
study E-STYPE
of O
traditional O
Chinese O
medicine O
prolonging O
the O
survival O
of O
advanced O
gastric O
cancer O
patients O
by O
regulating O
the O
immunosuppressive O
cell O
population O
A O
study B-STYPE
protocol E-STYPE
for O
a O
multicenter B-STYPE
, I-STYPE
randomized I-STYPE
controlled I-STYPE
trail E-STYPE
BSXiaotingPan S-AUTH
 
Nanjing O
BSXiaotingPan S-AUTH
BS B-AUTH
Xiaoting I-AUTH
Pan E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
BSHeyunTao S-AUTH
 
Nanjing O
BSHeyunTao S-AUTH
BS B-AUTH
Heyun I-AUTH
Tao E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
BSMengjunNie S-AUTH
 
Nanjing O
BSMengjunNie S-AUTH
BS B-AUTH
Mengjun I-AUTH
Nie E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
BSYuanjieLiu S-AUTH
 
Nanjing O
BSYuanjieLiu S-AUTH
BS B-AUTH
Yuanjie I-AUTH
Liu E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
BSPanHuang S-AUTH
 
Traditional O
Chinese O
Medicine O
Hospital O
of O
Zhangjiagang O
, O
d O
Changzhou O
TCM O
Hospital O
, O
e O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Kunshan O
, O
f O
Jiangsu O
Cancer O
Hospital O
, O
g O
Nanjing O
Drum O
Tower O
Hospital O
 
China O
BSPanHuang S-AUTH
BS B-AUTH
Pan I-AUTH
Huang E-AUTH
Traditional O
Chinese O
Medicine O
Hospital O
of O
Zhangjiagang O
, O
d O
Changzhou O
TCM O
Hospital O
, O
e O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Kunshan O
, O
f O
Jiangsu O
Cancer O
Hospital O
, O
g O
Nanjing O
Drum O
Tower O
Hospital O
 
China O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Zhangjiagang O
, O
d O
Changzhou O
TCM O
Hospital O
, O
e O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Kunshan O
, O
f O
Jiangsu O
Cancer O
Hospital O
, O
g O
Nanjing O
Drum O
Tower O
Hospital O
China O
China O
MSShenlinLiu S-AUTH
 
Nanjing O
MSShenlinLiu S-AUTH
MS B-AUTH
Shenlin I-AUTH
Liu E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
PhDWeiSun S-AUTH
 
Nanjing O
PhDWeiSun S-AUTH
PhD O
Wei B-AUTH
Sun E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
PhDJianWu S-AUTH
 
Nanjing O
PhDJianWu S-AUTH
PhD O
Jian B-AUTH
Wu E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
PhDTingMa S-AUTH
PhDTingMa S-AUTH
PhD O
Ting B-AUTH
Ma E-AUTH
BSAnweiDai S-AUTH
BSAnweiDai S-AUTH
BS O
Anwei B-AUTH
Dai E-AUTH
PhDJianweiLu S-AUTH
PhDJianweiLu S-AUTH
PhD O
Jianwei B-AUTH
Lu E-AUTH
PhDBaoruiLiu S-AUTH
PhDBaoruiLiu S-AUTH
PhD O
Baorui B-AUTH
Liu E-AUTH
PhDXiZou S-AUTH
 
Nanjing O
PhDXiZou S-AUTH
PhD O
Xi B-AUTH
Zou E-AUTH
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
MSQingminSun S-AUTH
sunqingminnjmu@163.com O
 
Nanjing O
MSQingminSun S-AUTH
MS O
Qingmin B-AUTH
Sun E-AUTH
sunqingminnjmu@163.com O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
 
Nanjing O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
, O
b O
No O
. O
1 O
Clinical O
Medical O
College O
Nanjing O
University O
of O
Chinese O
Medicine O
Nanjing O
Nanjing O
NieMLiu S-AUTH
NieMLiu S-AUTH
Nie B-AUTH
M I-AUTH
Liu E-AUTH
HuangPLiu S-AUTH
HuangPLiu S-AUTH
Huang B-AUTH
P I-AUTH
Liu E-AUTH
LuJLiu S-AUTH
LuJLiu S-AUTH
Lu B-AUTH
J I-AUTH
Liu E-AUTH
Ethic O
Committee O
of O
Affiliated O
Hospital O
 
Nanjing O
University O
of O
Chinese O
Medicine O
Ethic O
Committee O
of O
Affiliated O
Hospital O
Nanjing O
University O
of O
Chinese O
Medicine O
The O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Province O
Hospital O
of O
Chinese O
Medicine O
Nanjing O
 
China O
Nanjing O
China O
A O
clinical B-STYPE
study E-STYPE
of O
traditional O
Chinese O
medicine O
prolonging O
the O
survival O
of O
advanced O
gastric O
cancer O
patients O
by O
regulating O
the O
immunosuppressive O
cell O
population O
A O
study B-STYPE
protocol E-STYPE
for O
a O
multicenter O
, O
randomized B-STYPE
controlled I-STYPE
trail E-STYPE
10.1097 O
/ O
MD.0000000000019757 O
Received O
: O
4 O
March O
2020 O
/ O
Accepted O
: O
5 O
March O
2020 O
 
Gastric O
cancer O
( O
GC O
) O
is O
an O
important O
disease O
with O
high O
morbidity O
and O
mortality O
globally O
, O
which O
ranks O
the O
fifth O
most O
frequently O
diagnosed O
cancer O
and O
the O
third O
leading O
cause O
of O
cancer O
death O
. O
In O
2018 O
, O
over O
1,000,000 O
new O
cases O
were O
diagnosed O
with O
GC O
and O
approximately O
783,000 O
deaths O
( O
equating O
to O
1 O
in O
12 O
deaths O
worldwide O
) O
. O
[ O
1 O
] O
Most O
patients O
( O
> O
70 O
% O
) O
with O
GC O
are O
diagnosed O
at O
the O
advanced O
stage O
, O
[ O
2 O
] O
as O
a O
consequence O
, O
it O
shows O
a O
disappointing O
result O
. O
[ O
3,4 O
] O
Accumulating O
evidence O
shows O
that O
only O
5 O
% O
of O
patients O
with O
metastatic O
cancer O
are O
still O
alive O
5 O
years O
after O
diagnosis O
. O
[ O
5 O
] O
In O
recent O
years O
, O
immune O
microenvironment O
has O
been O
increasingly O
valued O
for O
its O
crucial O
role O
in O
the O
process O
of O
GC O
onset O
and O
progression O
. O
[ O
6][7][8 O
] O
Although O
surgical O
resection O
, O
chemotherapy O
, O
radiotherapy O
, O
biologic O
therapeutic O
agents O
, O
and O
other O
measures O
have O
been O
used O
to O
improve O
the O
therapeutic O
efficacy O
of O
GC O
, O
[ O
9 O
] O
the O
prognosis O
is O
still O
dismal O
. O
[ O
10 O
] O
Thus O
, O
it O
is O
important O
to O
explore O
new O
strategies O
to O
prolong O
the O
survival O
, O
improve O
the O
quality O
of O
life O
of O
the O
advanced O
GC O
patients O
. O
Fortunately O
, O
traditional O
Chinese O
medicine O
( O
TCM O
) O
has O
its O
unique O
advantages O
in O
preventing O
and O
treating O
GC O
[ O
11,12 O
] O
and O
it O
also O
has O
an O
efficacy O
in O
improving O
immune O
function O
. O
[ O
13 O
] O
The O
JPYZXZ O
decoction O
is O
a O
traditional O
Chinese O
herbal O
formulation O
created O
by O
Professor O
Shenlin O
Liu O
, O
the O
national O
famous O
Chinese O
Physician O
. O
JPYZXZ O
decoction O
is O
composed O
of O
12 O
kinds O
of O
Chinese O
herbal O
medicine O
, O
as O
is O
shown O
in O
Table O
1 O
. O
Our O
 
The O
datasets O
generated O
during O
and/or O
analyzed O
during O
the O
current O
study O
are O
not O
publicly O
available O
, O
but O
are O
available O
from O
the O
corresponding O
author O
on O
reasonable O
request O
. O
 
previous O
studies O
[ O
14 O
] O
have O
illustrated O
that O
JPYZXZ O
plays O
a O
critical O
role O
in O
improving O
cancer O
- O
related O
fatigue O
and O
prolonging O
survival O
in O
patients O
with O
advanced O
GC O
and O
it O
has O
been O
used O
to O
treat O
GC O
patients O
in O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
for O
many O
years O
. O
The O
aim O
of O
our O
present O
study O
is O
to O
explore O
the O
efficacy O
and O
safety O
of O
JPYZXZ S-DESC
decoction O
in O
advanced O
GC O
using O
a O
multicenter B-STYPE
randomized I-STYPE
controlled I-STYPE
trail E-STYPE
. O
Meanwhile O
, O
the O
changes O
of O
immunosuppressive O
cell O
population O
in O
peripheral O
blood O
of O
advanced O
GC O
patients O
will O
be O
detected O
to O
demonstrate O
the O
mechanism O
of O
JPYZXZ S-DESC
decoction O
. O
 
This O
is O
a O
prospective B-STYPE
, I-STYPE
multicenter I-STYPE
, I-STYPE
randomized I-STYPE
controlled I-STYPE
trial E-STYPE
lasting O
1.5 O
years O
in O
6 O
locations O
, O
including O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
, O
Jiangsu O
Cancer O
Hospital O
, O
Nanjing O
Drum O
Tower O
Hospital O
, O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Kunshan O
, O
Changzhou O
TCM O
Hospital O
and O
Traditional O
Chinese O
Medicine O
Hospital O
of O
Zhangjiagang O
. O
A O
total O
of O
210 O
eligibility O
patients O
with O
advanced O
GC O
will O
be O
enrolled O
in O
this O
trail O
. O
All O
the O
patients O
will O
be O
randomly O
assigned O
into O
2 O
groups O
( O
in O
a O
ratio O
of O
2:1 O
) O
: O
140 O
in O
the O
treatment B-DESC
group E-DESC
( O
chemotherapy S-DESC
plus B-DESC
JPYZXZ E-DESC
granules O
) O
and O
70 O
in O
the O
control B-DESC
group E-DESC
( O
chemotherapy S-DESC
alone O
) O
. O
The O
study O
protocol O
has O
been O
approved O
by O
the O
Ethic O
Committee O
of O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
( O
Number O
2019NL-166 O
- O
02 O
) O
, O
and O
it O
will O
be O
conducted O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
strictly O
. O
The O
study O
flowchart O
has O
been O
shown O
in O
Figure O
1 O
. O
 
After O
obtaining O
informed O
consent O
from O
eligible O
participants O
, O
researchers O
will O
upload O
the O
basic O
information O
. O
Then O
with O
the O
help O
of O
the O
third O
- O
party O
software O
Medroad O
Cloud O
, O
the O
random O
number O
will O
be O
given O
( O
https://sci.medroad.cn/ O
) O
. O
The O
participants O
will O
be O
randomly O
divided O
into O
the O
chemotherapy B-DESC
alone E-DESC
and O
chemotherapy S-DESC
plus B-DESC
JPYZXZ E-DESC
granules O
groups O
. O
 
A O
total O
of O
210 O
patients O
with O
advanced O
GC O
will O
be O
recruited O
in O
this O
clinical O
trail O
. O
The O
purpose O
, O
benefits O
and O
potential O
risks O
of O
this O
trail O
and O
other O
information O
will O
be O
informed O
to O
the O
patients O
in O
detail O
. O
All O
the O
patients O
participating O
in O
this O
trail O
are O
entirely O
voluntary O
, O
and O
they O
can O
also O
withdraw O
at O
any O
time O
during O
the O
whole O
trail O
without O
any O
consequence O
. O
Written O
consent O
will O
be O
obtained O
from O
each O
eligibility O
patient O
before O
them O
participating O
in O
the O
study O
. O
( O
1 O
) O
Patients O
who O
is O
unable O
to O
swallow O
oral O
medications O
including O
with O
digestive O
tract O
obstruction O
and O
jejunostomy O
; O
( O
2 O
) O
Patients O
with O
symptomatic O
brain O
metastasis O
or O
mental O
disorder O
; O
( O
3 O
) O
Patients O
with O
severe O
cardiovascular O
disease O
, O
chronic O
liver O
disease O
, O
kidney O
disease O
or O
blood O
disease O
; O
( O
4 O
) O
Patients O
whose O
laboratory O
examination O
before O
enrollment O
is O
abnormal O
according O
to O
the O
following O
criteria O
: O
Blood O
routine O
examination O
: O
ANC O
< O
2.0 O
Â O
10 O
9 O
/L O
, O
Hb O
< O
90 O
g O
/ O
L O
, O
PLT O
< O
80 O
Â O
10 O
9 O
/L O
, O
Renal O
function O
: O
Cr O
> O
1.5 O
Â O
upper O
normal O
limit O
( O
UNL O
) O
; O
2.5.2 O
. O
The O
treatment O
group O
. O
Total O
of O
140 O
patients O
in O
the O
treatment O
group O
will O
be O
treated O
with O
chemotherapy S-DESC
combined B-DESC
with I-DESC
JPYZXZ E-DESC
decoction O
. O
The O
chemotherapy S-DESC
regimens O
will O
be O
the O
same O
as O
the O
control B-DESC
group E-DESC
and O
the O
JPYZXZ S-DESC
decoction O
, O
available O
in O
the O
forms O
of O
granules O
, O
should O
be O
taken O
at B-DOSAGE
least I-DOSAGE
6 I-DOSAGE
months I-DOSAGE
, I-DOSAGE
per I-DOSAGE
bag I-DOSAGE
twice I-DOSAGE
daily I-DOSAGE
, I-DOSAGE
add I-DOSAGE
boiled I-DOSAGE
water I-DOSAGE
in I-DOSAGE
it I-DOSAGE
and I-DOSAGE
mix I-DOSAGE
up I-DOSAGE
it I-DOSAGE
, I-DOSAGE
150 I-DOSAGE
ml I-DOSAGE
each I-DOSAGE
time E-DOSAGE
. O
 
The O
time O
- O
points O
of O
assessment O
is O
listed O
in O
Table O
2 O
. O
2.6.1 O
. O
Primary O
outcomes O
. O
The O
primary O
outcomes O
include O
1year O
survival O
rate O
, O
progression B-METRIC
- I-METRIC
free I-METRIC
survival E-METRIC
, O
and O
overall O
survival O
( O
OS O
) O
. O
One O
- O
year O
survival O
rate O
= O
( O
the O
number O
of O
patients O
still O
alive O
after O
1 O
year O
of O
follow O
- O
up O
/ O
the O
total O
number O
of O
patients O
followed O
up O
) O
Â O
100 O
% O
. O
Progression B-METRIC
- I-METRIC
free I-METRIC
survival E-METRIC
means O
the O
time O
from O
the O
start O
of O
treatment O
to O
recurrence O
or O
death O
due O
to O
any O
causes O
. O
OS O
is O
the O
time O
from O
the O
beginning O
of O
diagnosis O
to O
death O
for O
any O
causes O
. O
All O
of O
the O
indicators O
will O
be O
calculated O
at O
the O
end O
of O
the O
trail O
. O
 
2.6.3 O
. O
Safety O
evaluation O
. O
Blood O
routine O
, O
Liver O
function O
, O
Renal O
function O
, O
and O
ECG O
will O
be O
monitored O
regularly O
to O
evaluate O
the O
safety O
of O
JPYZXZ S-DESC
decoction O
. O
 
Although O
adverse O
effect O
of O
JPYZXZ S-DESC
has O
not O
been O
observed O
in O
preclinical O
studies O
, O
all O
the O
researchers O
should O
pay O
close O
attention O
to O
possible O
adverse O
reactions O
, O
such O
as O
vomiting O
. O
Any O
adverse O
events O
occurred O
during O
the O
trail O
should O
be O
recorded O
in O
" O
Adverse O
events O
form O
" O
and O
the O
treatment O
process O
and O
results O
also O
need O
to O
be O
recorded O
in O
detail O
. O
When O
serious O
adverse O
events O
appeared O
, O
researchers O
should O
terminate O
the O
study O
of O
the O
participant O
of O
this O
case O
and O
fill O
out O
the O
" O
serious O
adverse O
events O
form O
" O
in O
truth O
. O
Every O
adverse O
event O
needs O
to O
be O
reported O
to O
the O
ethic O
committee O
of O
Affiliated O
Hospital O
of O
Nanjing O
University O
of O
Chinese O
Medicine O
. O
 
According O
to O
our O
previous O
study O
, O
the O
average O
survival O
time O
of O
advanced O
GC O
patients O
treated O
with O
chemotherapy S-DESC
is O
257.92 O
± O
16.56 O
days O
. O
Considering O
that O
the O
minimum O
error O
clinical O
accepted O
is O
3.5 O
% O
, O
a O
is O
0.05 O
and O
test O
efficiency O
is O
80 O
% O
. O
The O
sample O
size O
is O
calculated O
by O
the O
following O
formula O
: O
 
Considering O
20 O
% O
of O
the O
drop O
rate O
, O
allocating O
patients O
at O
a O
ratio O
of O
2:1 O
, O
the O
total O
sample O
size O
is O
210 O
( O
140 O
in O
chemotherapy S-DESC
plus B-DESC
JPYZXZ E-DESC
group O
and O
70 O
in O
chemotherapy B-DESC
alone E-DESC
group O
) O
. O
 
2.9 O
. O
Statistical O
analysis O
SPSS O
18.0 O
and O
other O
statistics O
software O
will O
be O
used O
to O
analyze O
the O
outcomes O
. O
Quantitative O
data O
will O
be O
expressed O
as O
the O
mean O
± O
standard O
deviation O
, O
and O
T O
test O
will O
be O
used O
to O
compare O
the O
data O
between O
2 O
groups O
. O
Qualitative O
data O
will O
be O
calculated O
by O
chisquare O
test O
and O
Fisher O
test O
. O
Quality O
of O
life O
analysis O
will O
be O
performed O
by O
repeated O
measures O
of O
variance O
. O
The O
OS O
and O
median O
survival O
will O
be O
analyzed O
by O
Kaplan O
- O
Meier O
. O
All O
data O
will O
be O
analyzed O
with O
a O
2-sided O
test O
and O
P O
.05 O
is O
considered O
statistically O
significant O
. O
 
This O
clinical O
study O
started O
in O
July O
2019 O
and O
is O
scheduled O
to O
end O
in O
June O
2022 O
. O
So O
far O
, O
we O
have O
received O
the O
ethical O
approval O
and O
registered O
at O
Chinese O
Clinical O
Trail O
Registry O
( O
www.chictr.org.cn O
ChiCTR1900028147 O
) O
. O
Patients O
recruitment O
is O
in O
progress O
when O
the O
manuscript O
submitted O
. O